https://www.gosh.nhs.uk/our-research/our-research-infrastructure/nihr-great-ormond-street-hospital-brc/brc-news/nihr-gosh-brc-spinout-orchard-therapeutics-signs-strategic-agreement-gsk/
NIHR GOSH BRC spinout Orchard Therapeutics signs strategic agreement with GSK
13 Apr 2018, 1:10 p.m.
GSK and Orchard Therapeutics today announced a strategic agreement, under which GSK will transfer its portfolio of approved and investigational rare disease gene therapies to Orchard, securing the continued development of the programmes and access for patients.Orchard Therapeutics is a biotechnology company that develops transformative gene therapies for life threatening rare diseases. Orchard’s founding scientists include NIHR GOSH BRC researchers Professor Bobby Gaspar, Adrian Thrasher and Waseem Qasim. This acquisition strengthens Orchard’s position as a global leader in gene therapy for rare diseases and GSK will continue to invest in the development of its platform capabilities in cell and gene therapies, with a focus on oncology.
This agreement is evidence of GOSH BRC’s continued success in accelerating the delivery of new medicines for patient benefit and is testament to the GOSH BRC’s unique expertise in novel therapies for rare diseases.
Under the agreement, GSK will become an investor in Orchard Therapeutics, receiving a 19.9% equity stake along with a seat on the company’s board. GSK will also receive financial considerations in the form of royalties and commercial milestone payments related to the acquired portfolio. GSK and Orchard will exchange manufacturing, technical and commercial insights and learnings on the development of gene therapy medicines to ensure the success of the assets.
The acquisition of GSK’s programmes complements Orchard’s pipeline of clinical and preclinical gene therapies for primary immune deficiencies and inherited metabolic disorders.
New study finds that nasal cells protect against Covid-19 in children
New research shows that children are less likely than adults to develop severe Covid because cells in their nose are better at fighting off the virus.
New plan announced to get more children access to gene therapy treatments
Great Ormond Street Hospital (GOSH) has announced plans to revolutionise how children living with a rare disease can gain access to life-changing treatments.
First-of-its-kind study into the Ketogenic diet
A ketogenic diet, which is low in carbohydrates and high in fat, shows promise as an alternative treatment option for infants with drug-resistant epilepsy.
Raising awareness on Rare Disease Day
To celebrate Rare Disease Day we invited patients and their families to try out 13 different hands-on and interactive fun and educational science and research activities for children and adults.